Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 24-Apr-2014
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 22)
Release
Date
 [down]
Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
24-Apr-14ValuEngine, Inc.N/AValuEngine Industry Report for Medical Instruments17$49  View Abstract
24-Apr-14New Constructs, LLCN/ANAVB: Due Diligence Review: Forensic Earnings and Valuation5$25  View Abstract
23-Apr-14Thomson Reuters Stock ReportN/AThomson Reuters Stock Report - NAVIDEA BIOPHARMACEUTICALS INC (NAVB-A)11$25  View Abstract
18-Apr-14Reuters Investment ProfileN/ANavidea Biopharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$138  View Abstract
18-Apr-14Jefferson ResearchN/AJefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of NAVIDEA BIOPHARMACEUTICALS including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.11$20  View Abstract
17-Apr-14Ford Investor Services, Inc.N/AValue Graph: NAVIDEA BIOPHARM -- NAVB1$11.50  View Abstract
17-Apr-14Ford Investor Services, Inc.N/AIndustry Value Graph: KOOL , FLDM , GNMK , IMSC , MGCD , NAVB , SURG -- MEDICAL SUPPLIES & EQUIPMENT3$34.50  View Abstract
13-Apr-14TheStreet.com RatingsN/ATheStreet.com Ratings Stock Report For: NAVIDEA BIOPHARMACEUTICALS (NAVB)5$10  View Abstract
11-Apr-14GlobalDataGlobalDataNavidea Biopharmaceuticals, Inc. (NAVB) - Financial and Strategic SWOT Analysis Review41$125  View Abstract
8-Apr-14Zacks Investment Research Inc.N/ANAVIDEA BIOPHAR (NAVB) Zacks Company Snapshot1$11.50  View Abstract
Next 12

Independent Reports (Showing 1 to 10 of 22)
Release
Date
 [down]
Contributor Author Title Pages Price More Info
24-Apr-14ValuEngine, Inc.N/AValuEngine Industry Report for Medical Instruments17$49View Abstract
24-Apr-14New Constructs, LLCN/ANAVB: Due Diligence Review: Forensic Earnings and Valuation5$25View Abstract
23-Apr-14Thomson Reuters Stock ReportN/AThomson Reuters Stock Report - NAVIDEA BIOPHARMACEUTICALS INC (NAVB-A)11$25View Abstract
18-Apr-14Reuters Investment ProfileN/ANavidea Biopharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.12$138View Abstract
18-Apr-14Jefferson ResearchN/AJefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of NAVIDEA BIOPHARMACEUTICALS including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.11$20View Abstract
17-Apr-14Ford Investor Services, Inc.N/AValue Graph: NAVIDEA BIOPHARM -- NAVB1$11.50View Abstract
17-Apr-14Ford Investor Services, Inc.N/AIndustry Value Graph: KOOL , FLDM , GNMK , IMSC , MGCD , NAVB , SURG -- MEDICAL SUPPLIES & EQUIPMENT3$34.50View Abstract
13-Apr-14TheStreet.com RatingsN/ATheStreet.com Ratings Stock Report For: NAVIDEA BIOPHARMACEUTICALS (NAVB)5$10View Abstract
11-Apr-14GlobalDataGlobalDataNavidea Biopharmaceuticals, Inc. (NAVB) - Financial and Strategic SWOT Analysis Review41$125View Abstract
8-Apr-14Zacks Investment Research Inc.N/ANAVIDEA BIOPHAR (NAVB) Zacks Company Snapshot1$11.50View Abstract
Next 12

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.


Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.